Ab­b­vie, Prin­cip­ia join forces on im­muno­pro­tea­some in­hibitors; Scripps de­vel­ops hero­in vac­cine, FDA fast tracks NGF pain drug

→  Ab­b­vie and Prin­cip­ia are col­lab­o­rat­ing to de­vel­op oral im­muno­pro­tea­some in­hibitors to treat au­toim­mune dis­ease us­ing nov­el tech­nol­o­gy dis­cov­ered at Prin­cip­ia. Fi­nan­cial terms were not dis­closed, but the two will work to­geth­er dur­ing de­vel­op­ment and pre­clin­i­cal test­ing. Then Ab­b­vie will move the tech­nol­o­gy for­ward to the clin­i­cal phase.

→  Sci­en­tists at the Scripps Re­search In­sti­tute have de­vel­oped a vac­cine against an un­usu­al tar­get – hero­in. The re­searchers gave their vac­cine to rhe­sus mon­keys and showed that it pre­vent­ed them from ex­pe­ri­enc­ing a high when ex­posed to the drug months lat­er. The re­searchers will be­gin test­ing the vac­cine, which they be­lieve will help ad­dicts avoid re­laps­ing. The vac­cine does not work for oth­er opi­oids, nor does it pre­vent over­dos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER